{"title":"Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference - Research on Metastasis: part 2.","authors":"Suzanne A Eccles","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The Metastasis and the Tumor Microenvironment Conference, held in Philadelphia, included topics covering new research developments in the field of metastasis and tumor microenvironment. This conference report highlights selected presentations on translation targets from a clinical perspective, antibody inhibitors of TGFβ for metastasis suppression, metastasis in bladder and lung cancer, c-ErbB2/HER2 expression in ductal carcinomas in situ and breast cancer, targeting Hsp90 chaperones in solid cancers, peritoneal carcinomas, and the discovery and exploitation of RANK ligands in bone metastasis. Investigational drugs discussed include the humanized antibody against TGFβ fresolimumab (GC-1008; Genzyme), the anti-VEGFR1 antibody icrucumab (IMC-18F1; ImClone Systems) and the novel Hsp90 inhibitor NVP-AUY-922 (AUY-922, VER-52296; Novartis).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 11","pages":"768-71"},"PeriodicalIF":0.0000,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Idrugs","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The Metastasis and the Tumor Microenvironment Conference, held in Philadelphia, included topics covering new research developments in the field of metastasis and tumor microenvironment. This conference report highlights selected presentations on translation targets from a clinical perspective, antibody inhibitors of TGFβ for metastasis suppression, metastasis in bladder and lung cancer, c-ErbB2/HER2 expression in ductal carcinomas in situ and breast cancer, targeting Hsp90 chaperones in solid cancers, peritoneal carcinomas, and the discovery and exploitation of RANK ligands in bone metastasis. Investigational drugs discussed include the humanized antibody against TGFβ fresolimumab (GC-1008; Genzyme), the anti-VEGFR1 antibody icrucumab (IMC-18F1; ImClone Systems) and the novel Hsp90 inhibitor NVP-AUY-922 (AUY-922, VER-52296; Novartis).
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
